Litcius/Paper detail

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Muñoz, Hun Ju Lee, Won Seog Kim, Ranjana H. Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John Radford

2021The Lancet Haematology160 citationsDOI

Topics & Concepts

MedicineBrentuximab vedotinOpen labelOncologyInternal medicineChemotherapyHodgkin lymphomaPhases of clinical researchLymphomaRandomized controlled trialLymphoma Diagnosis and TreatmentEsophageal Cancer Research and TreatmentRadiopharmaceutical Chemistry and Applications
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial | Litcius